Evidence map›Paper›PMID 39399554›Full record

ArticleNeurology. Clinical practice2025

Net Health System Costs of Parkinson Disease: A Propensity Score-Matched Health Administrative Data Cohort Study in Ontario, Canada.

Laura C Maclagan, Abby Emdin, Longdi Fu, Jun Guan, Claire de Oliveira, Connie Marras, Susan E Bronskill

Abstract read
In one paragraph

Article in Neurology. Clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Laura C MaclaganLife Stage Research Program (LCM, LF, JG, CO, CM, SEB), ICES; Division of Epidemiology (AE, SEB) and Institute of Health Policy, Management & Evaluation (CO, CM, SEB), Dalla Lana School of Public Health, University of Toronto; Edmond J Safra Program in Parkinson Disease (CM), Toronto Western Hospital; Sunnybrook Research Institute (SEB), Sunnybrook Health Sciences Centre; and Women's College Research Institute (SEB), Women's College Hospital, Toronto, Ontario Canada.ORCID https://orcid.org/0000-0002-2355-6939
Abby EmdinLife Stage Research Program (LCM, LF, JG, CO, CM, SEB), ICES; Division of Epidemiology (AE, SEB) and Institute of Health Policy, Management & Evaluation (CO, CM, SEB), Dalla Lana School of Public Health, University of Toronto; Edmond J Safra Program in Parkinson Disease (CM), Toronto Western Hospital; Sunnybrook Research Institute (SEB), Sunnybrook Health Sciences Centre; and Women's College Research Institute (SEB), Women's College Hospital, Toronto, Ontario Canada.ORCID https://orcid.org/0009-0002-0640-7365
Longdi FuLife Stage Research Program (LCM, LF, JG, CO, CM, SEB), ICES; Division of Epidemiology (AE, SEB) and Institute of Health Policy, Management & Evaluation (CO, CM, SEB), Dalla Lana School of Public Health, University of Toronto; Edmond J Safra Program in Parkinson Disease (CM), Toronto Western Hospital; Sunnybrook Research Institute (SEB), Sunnybrook Health Sciences Centre; and Women's College Research Institute (SEB), Women's College Hospital, Toronto, Ontario Canada.ORCID https://orcid.org/0009-0006-5816-0922
Jun GuanLife Stage Research Program (LCM, LF, JG, CO, CM, SEB), ICES; Division of Epidemiology (AE, SEB) and Institute of Health Policy, Management & Evaluation (CO, CM, SEB), Dalla Lana School of Public Health, University of Toronto; Edmond J Safra Program in Parkinson Disease (CM), Toronto Western Hospital; Sunnybrook Research Institute (SEB), Sunnybrook Health Sciences Centre; and Women's College Research Institute (SEB), Women's College Hospital, Toronto, Ontario Canada.ORCID https://orcid.org/0009-0007-0282-8724
Claire de OliveiraLife Stage Research Program (LCM, LF, JG, CO, CM, SEB), ICES; Division of Epidemiology (AE, SEB) and Institute of Health Policy, Management & Evaluation (CO, CM, SEB), Dalla Lana School of Public Health, University of Toronto; Edmond J Safra Program in Parkinson Disease (CM), Toronto Western Hospital; Sunnybrook Research Institute (SEB), Sunnybrook Health Sciences Centre; and Women's College Research Institute (SEB), Women's College Hospital, Toronto, Ontario Canada.ORCID https://orcid.org/0000-0003-3961-6008
Connie MarrasLife Stage Research Program (LCM, LF, JG, CO, CM, SEB), ICES; Division of Epidemiology (AE, SEB) and Institute of Health Policy, Management & Evaluation (CO, CM, SEB), Dalla Lana School of Public Health, University of Toronto; Edmond J Safra Program in Parkinson Disease (CM), Toronto Western Hospital; Sunnybrook Research Institute (SEB), Sunnybrook Health Sciences Centre; and Women's College Research Institute (SEB), Women's College Hospital, Toronto, Ontario Canada.ORCID https://orcid.org/0000-0002-9236-9328
Susan E BronskillLife Stage Research Program (LCM, LF, JG, CO, CM, SEB), ICES; Division of Epidemiology (AE, SEB) and Institute of Health Policy, Management & Evaluation (CO, CM, SEB), Dalla Lana School of Public Health, University of Toronto; Edmond J Safra Program in Parkinson Disease (CM), Toronto Western Hospital; Sunnybrook Research Institute (SEB), Sunnybrook Health Sciences Centre; and Women's College Research Institute (SEB), Women's College Hospital, Toronto, Ontario Canada.ORCID https://orcid.org/0000-0002-7341-0655

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objectives: Few estimates of the long-term health system costs of Parkinson disease by phase of disease are available. We estimated 10-year and phase-based net health system costs of Parkinson disease before and after case ascertainment. Methods: Using population-based linked administrative databases from Ontario, Canada, we identified 43,149 community-dwelling persons with incident Parkinson disease aged 40 years and older between 2009 and 2018 using a validated algorithm. These individuals were matched 1:1 to controls without Parkinson disease based on demographics and a propensity score. We calculated phase-based, net health system costs from the provincial government perspective during the preascertainment (3 years before index), initial (1 year after index), early continuing (>1-6 years after index), later continuing (>6-10 years after index), and terminal (1 year before death, if applicable) phases (standardized to 2020 $CAD and calculated on an annual basis). By applying survival probabilities to monthly cost estimates, we also determined 10-year net health system costs, stratified by sex and age. Results: Annual mean net costs of Parkinson disease were lowest in the preascertainment phase ($212 CAD, 95% CI [$20-$404]), intermediate in the initial phase ($4,576 (95% CI [$4,217-$4,935]), and higher in the early continuing phase ($7,078, 95% CI [$6,717-$7,438]). The later continuing phase ($12,500, 95% CI [$12,060-$12,940]) and the terminal phase ($13,933, 95% CI [$13,123-$14,743]) showed the highest costs. The 10-year net cost of Parkinson disease was $82,153 (95% CI [$77,965-$86,341]) and was significantly higher in women ($89,773, 95% CI [$83,306-$96,240]) than in men ($76,469, 95% CI [$70,983-$81,953]) and older individuals ($92,197, 95% CI [$87,087-$97,307]), compared with younger individuals ($62,580, 95% CI [$55,346-$69,814]). Over the 10-year period, hospital, nursing home, and home care were the largest contributors to costs of Parkinson disease. Discussion: Health system costs of Parkinson disease are substantial, particularly in the later phases. Interventions to reduce avoidable use of hospital and nursing home services by persons living with Parkinson disease may provide better quality of life and be cost saving from the health system perspective.

Identifiers

PMID39399554
PMCPMC11464220

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.